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Abstract 
Background: Stressful life events influence the course of affective disorders, however, the mechanisms by which 
they bring about phenotypic change are not entirely known.
Methods: We explored the role of DNA methylation in response to recent stressful life events in a cohort of bipolar 
patients from the longitudinal PsyCourse study (n = 96). Peripheral blood DNA methylomes were profiled at two time 
points for over 850,000 methylation sites. The association between impact ratings of stressful life events and DNA 
methylation was assessed, first by interrogating methylation sites in the vicinity of candidate genes previously impli‑
cated in the stress response and, second, by conducting an exploratory epigenome‑wide association analysis. Third, 
the association between epigenetic aging and change in stress and symptom measures over time was investigated.
Results: Investigation of methylation signatures over time revealed just over half of the CpG sites tested had an 
absolute difference in methylation of at least 1% over a 1‑year period. Although not a single CpG site withstood 
correction for multiple testing, methylation at one site (cg15212455) was suggestively associated with stressful life 
events (p < 1.0 × 10−5). Epigenetic aging over a 1‑year period was not associated with changes in stress or symptom 
measures.
Conclusions: To the best of our knowledge, our study is the first to investigate epigenome‑wide methylation across 
time in bipolar patients and in relation to recent, non‑traumatic stressful life events. Limited and inconclusive evi‑
dence warrants future longitudinal investigations in larger samples of well‑characterized bipolar patients to give a 
complete picture regarding the role of DNA methylation in the course of bipolar disorder.
Keywords: DNA methylation, Bipolar disorder, Stressful life events, Longitudinal, Epigenomics, Epigenetic aging
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/.
Background
Bipolar disorder (BD) remains an interesting candidate 
for neurobiological analyses owing to its heterogenous 
presentation and both genetic and environmental risk 
factors (Ludwig and Dwivedi 2016). While genome-wide 
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association studies (GWAS) in BD have identified dozens 
of associated variants, they have explained only a small 
fraction of overall disease liability (Stahl et  al. 2019). 
Therefore, the last decade has seen a shift towards inves-
tigating the complex interplay between genetic and envi-
ronmental risk factors (Sharma et al. 2016). Advances in 
technologies have supported high-throughput investiga-
tions of biological markers representative of environmen-
tal modulation of the genome. These biomarkers hold 
promise for stratifying symptom-based phenotypes and 
assessing the prognosis of individual patients (Kobeissy 
et  al. 2012). Moreover, these biomarkers could contrib-
ute to a more accurate multi-level diagnostic framework 
which relies on biological measures to supplement clini-
cal ratings of symptoms (Meana and Mollinedo-Gajate 
2017).
BD is a chronic, disabling, and severe mental ill-
ness characterized by recurrent depressive and manic 
episodes, somatic and psychiatric comorbidities, and 
functional impairments (Goodwin and Jamison 2007). 
Considering the high global burden and lifetime preva-
lence of bipolar spectrum disorders, estimated at approx-
imately 2.4% (Rowland and Marwaha 2018), there is a 
need to better understand the factors affecting its onset 
and course. The significance of environment, especially 
childhood trauma and stressful life events on the tra-
jectories of affective disorders, including vulnerability, 
onset, relapse and occurrence, has been well established 
(Aldinger and Schulze 2017; Lex et  al. 2017; Johnson 
2005; Alloy et  al. 2005; Paykel 2003). However, little is 
known about the mechanisms involved in the conse-
quences of such life events.
Recently, emphasis has been placed on the potential 
role of epigenetic variation in the etiopathogenesis of 
BD (Li et  al. 2015). Epigenetics is an adaptive mecha-
nism which can modulate the stress response through 
subtle gene expression modifications (Aas et  al. 2016). 
In particular, DNA methylation (DNAm), the addition 
of a methyl group to DNA, primarily at cytosine-guanine 
dinucleotides (CpG), may pose a “mechanism by which 
life-experiences become ‘embedded’ in the genome” 
(Marzi et al. 2018).
Increasing evidence from both animal and human 
data supports the epigenetic programming of genes in 
response to trauma and chronic stress. Consistent find-
ings have linked prenatal (Monk et al. 2012; Weaver et al. 
2004) and early-life adversities to epigenetic modifica-
tions of genes, especially those involved in the hypotha-
lamic–pituitary–adrenal (HPA) axis (Kular and Kular 
2018; McGowan et  al. 2009; Vinkers et  al. 2015; Jawor-
ska-Andryszewska and Rybakowski 2019). While sev-
eral studies have shown methylation changes associated 
with trauma during the adult period, few studies have 
investigated non-traumatic chronic stress (Matosin 
et al. 2017) or acute stressful life events. Candidate gene 
approaches in the general population have reported dif-
ferential methylation of CpGs in the vicinity of SLC6A4 
(Alasaari et al. 2012), TH (Myaki et al. 2015), and BDNF 
(Song et  al. 2014) in association with sustained work-
related stress. One study, which examined LINE-1 as a 
proxy for global methylation, found no signification asso-
ciations with chronic lifestyle stress (Duman and Canli 
2015). To the best of our knowledge, not a single study 
has explored epigenome-wide signatures of DNAm in 
relation to acute, non-traumatic stress in humans. With 
regards to BD, studies have investigated methylation dif-
ferences as both trait and state markers of the disorder 
in several promoter regions including SLC6A4, PPIEL31, 
BDNF, HCG9, KCNQ3, 5HTR1A and GPR24 (Ludwig 
and Dwivedi 2016; Fries et  al. 2016; Pishva et  al. 2014). 
Interestingly, evidence supports altered DNAm profiles 
for high-risk affected and even unaffected offspring of 
individuals with BD in comparison to low risk controls. 
Moreover, there seems to be a unique rate of change in 
DNAm over time for high risk individuals (Duffy et  al. 
2019). However, despite findings of differential epigenetic 
profiles, results have been inconsistent and there remains 
a need for genome-wide methylation studies, especially 
ones longitudinal in design.
This study aims to gain a better understanding of the 
role of epigenetic modifications, specifically DNAm, in 
relation to stress during the course of BD. Using repeated 
measures over a 1-year period, we explored the relation-
ship between DNAm and stressful life events in chronic 
BD patients. We took a two-pronged approach, first by 
interrogating CpGs in the vicinity of candidate genes 
previously implicated in the stress response and, second, 
by conducting an exploratory epigenome-wide analysis. 
Furthermore, we determined whether changes in symp-
tom and stress measures over time were associated with a 
DNAm-based age estimate and epigenetic aging.
Methods
Study sample
The study was conducted using data from the longitudi-
nal PsyCourse cohort. PsyCourse has been described in 
detail (Budde et  al. 2019). Briefly, PsyCourse is a multi-
site, naturalistic study, based in the German and Austrian 
population. Psychopathology, pharmacological treat-
ment, childhood trauma and current stressful life events 
were among other variables assessed at each of four visits 
(6-month intervals). Likewise, peripheral blood samples 
were collected at each visit, paving the way for a detailed 
analysis of the longitudinal correlation between disease 
status and peripheral biomarkers. For the purpose of this 
study, a subset of PsyCourse participants (n = 96) was 
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selected according to a DSM-IV diagnosis (American 
Psychiatric Association 2002) of type I or II BD, avail-
ability of genotype data and biomaterial, and completed 
childhood trauma and stressful life events question-
naires. Demographic and clinical characteristics of these 
patients are reported in Table 1. The study was approved 
by the local ethics committee for each study center and 
was carried out following the rules of the Declaration 




Current stressful life events were assessed with the Life 
Events Questionnaire (LEQ), a 79-item self-report instru-
ment that has been described in detail (Norbeck 1984; 
Sarason et  al. 1978). The LEQ covers a wide range of 
stressor exposure related to health, work, school, resi-
dence, love and marriage, family and friends, parenting, 
the personal sphere or social environment, finances, 
crime and legal matters. At each visit, participants 
reported whether they experienced any of the listed 
events in the last 6  months. When the patient experi-
enced a specific event, they rated: (1) the nature of the 
event (good/bad) and (2) the impact of the event on his/
her life (0–3). At each time point, adverse life events were 
summed to yield a stress score that reflects the impact 
ratings of all “bad” events. The same was done for the 
impact ratings of “good” events. A total score was also 
summed including impact ratings of both “bad” and 
“good” events. These three LEQ scores were used as out-
come measures in our association analyses.
Childhood trauma
The Childhood Trauma Screener (CTS) is a German, 
short version of the Childhood Trauma Questionnaire 
(Bernstein et  al. 1997, 2003; Grabe et  al. 2012). The 
screener includes five questions to assess sexual, physi-
cal and emotional abuse, as well as emotional and physi-
cal neglect. Validated threshold values (Glaesmer et  al. 
2013) were used to transform ratings for each item into 
a dichotomous scale in order to identify individuals with 
reported childhood trauma (yes/no). Details on reported 
childhood trauma and thresholds used can be found in 
Additional file 1: Table S1.
Symptom ratings
The Positive and Negative Syndrome Scale (PANSS) was 
used as a measure of psychopathology at the time of test-
ing (Kay et al. 1987). A continuous total score of the three 
subscales, i.e. positive, negative, and general symptoms 
was used. The Global Assessment of Functioning (GAF) 
score was used as a measure of psychosocial functioning 
(Luborsky 1962; Endicott et al. 1976). The Young Mania 
Rating Scale (YMRS) was used as a measure of manic 
symptoms in the last 48  h (Young et  al. 1978). Lastly, 
the Inventory of Depressive Symptomatology (IDS-C30), 
a 30-item rating scale, was used to assess the severity of 
depressive symptoms (Trivedi et al. 2004).
Analysis of DNA methylation
DNA samples
Genomic DNA was extracted from whole blood using the 
PerkinElmer Chemagen Kit (chemagic DNA Blood10k 
prefilling VD120419.che) and all samples were subse-
quently stored in a Hamilton Bios M system at − 80 °C. 
DNA quality was assessed using the  QIAxcl® system. 
DNA samples from baseline and 1-year follow-up visits 
were used to obtain methylation data. Prior to down-
stream analyses, potential population stratification was 
evaluated, and an initial step to remove European popu-
lation outliers was taken (Budde et  al. 2019). Thus, our 
sample consists of an ethnically homogenous population 
of Caucasians of European descent.
Table 1 Sample demographic and clinical characteristics
a Paired sample t-test







 Female 50 50
Age, mean ± SD 45.2 ± 12.4 46.17 ± 12.4
Duration of illness, 
mean ± SD
13.52 ± 11.8 14.66 ± 11.8
DSM‑IV diagnosis
 BD‑I 79 78
 BD‑II 17 17
Medication
 Combo therapy 81 75
 Monotherapy 14 16
 No meds 1 4
Childhood trauma (yes) 48 48
LEQ scores, mean ± SD
 Bad events 10.2 ± 13.8 6.3 ± 6.6 0.004b
 Good events 9.7 ± 10.2 8.4 ± 7.6 0.191b
 Total events 19.9 ± 18.4 14.1 ± 10.7 0.001b
Symptom ratings
 GAF, mean ± SD 61.5 ± 12.6 65.8 ± 12.4 0.032a
 YMRS sum, mean ± SD 3.9 ± 5.8 2.4 ± 3.7 0.216b
 IDS‑C30, mean ± SD 13.7 ± 11.0 10.6 ± 9.7 0.124b
 PANSS sum, mean ± SD 42.8 ± 11.8 39.2 ± 9.6 0.063b
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Illumina EPIC chip processing
Bisulfide conversion of DNA and processing of methyla-
tion arrays was accomplished in collaboration with the 
Institute of Human Genetics, University of Bonn, Ger-
many. Whole-blood genomic DNA diluted with water 
(50  ng/μl) was treated with sodium bisulfite using the 
 EpiTect® Bisulfite Kit from  QIAGEN® following the 
manufacturer’s protocol. DNAm was assessed using the 
Illumina Infinium Human MethylationEPIC BeadChip 
array (Illumina Inc., San Diego, CA, USA) according 
to the manufacturer’s instructions. To minimize batch 
effects during DNAm measurement, an algorithm for 
sample randomization was used for positioning samples 
onto 96-well plates according to exposures of interest and 
confounding variables (see Additional file 1).
Quality control and normalization
Quality control
The Bioconductor R package minfi was used to read raw 
intensity data files (.idat files) into R and for the subse-
quent quality control and normalization of methylation 
data (Aryee et al. 2014). Concordance between methyla-
tion-predicted and reported sex was confirmed. Filtering 
of poor-performing samples and probes was performed 
(see Additional file 1: Table S2). Probes with low detec-
tion p-values (> 0.05 in > 10% of samples) were excluded. 
Using the function dropLociWithSnps(), SNPs inside 
the probe body and at the nucleotide extension were 
removed according to a minor allele frequency ≥ 5% 
based on dbSNP. To prevent a possible gender effect, X 
and Y chromosomes were removed. According to a list 
previously published (Chen et  al. 2013), non-specific 
probes i.e. probes on the EPIC array that co-hybridize 
to alternate genomic sequences, were removed. Lastly, 
probes with a bead count < 3 were removed.
Normalization
Data were normalized using functional normalization 
(FunNorm), an extension of quantile normalization. Fun-
Norm uses internal control probes present on the array to 
infer between-array technical variation, by default using 
the first two principal components of the control probes 
(Fortin et  al. 2014). Density plots were used to evaluate 
the distribution of M-values before and after functional 
normalization (see Additional file 1: Fig. S1).
Technical batch effects were then identified using lin-
ear regressions to inspect the association of principal 
components of the methylation values with possible 
technical batches. Additionally, the R package shinyM-
ethyl was used for visual inspection of principle compo-
nent analysis (PCA) plots. Identified batch effects (i.e., 
array and slide) were removed using the Empirical Bayes’ 
method ComBat (Johnson et  al. 2007). Batch corrected 
M-values after ComBat were used for downstream analy-
ses (see Additional file  1: Fig. S2). According to inspec-
tion of PCA plots, a single sample remained an outlier 
after batch correction and was excluded.
Confounders
Considering cell-type composition is a confounding fac-
tor in epigenome-wide association studies (EWAS), the 
minfi function estimateCellcounts() was used to estimate 
the cell type composition for our samples. This func-
tion uses a modified version of the Houseman algorithm 
to obtain a cell counts vector for the six cell-types (i.e., 
CD4T, CD8T, NK, B cells, monocytes, and granulocytes) 
for each sample (Houseman et al. 2012).
Active smoking is another established modifier of DNA 
methylation (Lee and Pausova 2013). Methylation-based 
smoking scores were calculated based on the methyla-
tion profile of the 187 CpG sites identified in Zeilinger 
et  al. (2013). First, raw beta values were normalized 
using the Teschendorff et al. beta-mixture quantile dila-
tion (BMIQ) strategy (Teschendorff et al. 2013). Adjusted 
beta-values were then used for calculation of methyl-
ation-based smoking scores using methods previously 
described (Elliott et  al. 2014). The correlation between 
self-reported number of cigarettes smoked yearly and 
methylation-based smoking scores was assessed (Spear-
man’s ρ = 0.64; p < 0.001).
To rule out possible confounding effects of medication, 
5 samples were excluded in sensitivity analyses. These 
samples were participants who were not taking psycho-
tropic drugs at the time of testing. All other participants 
were taking at least one (monotherapy) or a combination 
(combo therapy) of the following (1) antidepressants, (2) 
antipsychotics, (3) mood stabilizers, (4) tranquilizers, or 
(5) other psychiatric medications.
Statistical analyses
All statistical analyses were performed in R version 3.4.4 
(http://www.r-proje ct.org/) (R Core Team 2014).
Change in methylation over time
The general “stability” of methylation over time was 
investigated. First, the absolute change in methylation 
β-values between baseline and 1-year follow-up vis-
its were calculated across all CpG sites. To determine 
whether differential methylation between visits remained 
significant after adjusting for known confounders, the 
package lme4 (Bates et al. 2015) was used to fit a linear 
mixed-effects model (LMM) with the dependent variable 
“M-value” and the independent variable “time”, adjusting 
for age, sex, DNAm smoking scores, and cell composition 
estimates. Patient ID was included as the random effect 
term.
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Candidate gene analysis
The association between LEQ scores and the interac-
tion between CT and total LEQ scores with DNAm 
was assessed via LMMs, adjusting for covariates as 
described above. We interrogated DNAm in the vicin-
ity of genes previously implicated in the HPA-axis (i.e. 
BDNF, FKBP5, IL6, SLC6A4, and OXTR). All probes on 
the EPIC array annotated to each of these five genes 
were identified. The number of probes per gene ranged 
from 22 to 124. We corrected for multiple testing on a 
gene-level by applying the false discovery (FDR) cor-
rection (Benjamini and Hochberg 1995) per gene, with 
FDR-corrected p-values ≤ 0.05 deemed significant. 
Afterwards, Bonferroni-correction was used to correct 
overall for the number of candidate-genes tested.
Exploratory EWAS
An exploratory EWAS was conducted. As a means 
of noise reduction, the top 10% of the most variable 
CpGs of the normalized, batch corrected M-values 
were extracted according to median absolute deviation 
(MAD) scores i.e. the median of the absolute devia-
tions from the data’s median. Associations between the 
most variable sites and LEQ scores and the interaction 
between childhood trauma and total LEQ scores were 
then tested using LMMs, adjusting for covariates as 
described above.
Epigenetic aging
DNAm-based age prediction was performed using the 
Horvath age estimation algorithm (Horvath 2013) with 
a freely available online tool (https ://dnama ge.genet ics.
ucla.edu/home) which predicts DNAm-age based on 
the methylation of 353 CpGs using an elastic net penal-
ized regression model. The difference between the esti-
mated epigenetic age and chronological age (Δage) and 
a measure of epigenetic age acceleration (AA), i.e., the 
residual from regressing DNAm age on chronological 
age, were calculated. LMMs were used to determine the 
effect of LEQ scores on Δage, adjusting for chronologi-
cal age, sex, DNAm smoking scores, cell composition 
estimates, and technical batch effects (sample slide and 
array). Additionally, the difference in symptom ratings 
and stress scores between visits were calculated. The 
association between the change in symptoms and LEQ 
scores between baseline and 1-year follow-up with AA 
at 1-year follow-up was determined via linear regres-
sion models, again controlling for chronological age, 
sex, DNAm smoking scores, cell composition estimates 
and technical batch effects.
Additional analyses
Nominally significant CpGs (unadjusted p < 0.05) asso-
ciated with total LEQ scores were used for gene-based 
enrichment analysis using the GOmeth function from 
the Bioconductor package missMethyl. GOmeth maps a 
vector of CpG sites to Entrez Gene IDs, and tests for 
gene ontology (GO) term pathway enrichment using a 
hypergeometric test (Geeleher et  al. 2013). Addition-
ally, the correlation between DNAm in blood and four 
brain regions was explored for the most suggestive 




The mean absolute difference in methylation (β) between 
visits 1 and 3 (|Δβ|) was calculated across all samples for 
all CpG sites (Fig. 1). Over the 1-year period, |Δβ| ranged 
from < 0.001 to 0.299 with an average change of 0.014. Of 
753,251 CpG sites, only 68 had an |Δβ| of 0.10 or more, 
while 8454 sites differed by at least 0.05 between visits. 
Just over half of the sites (428,610) showed an absolute 
difference in methylation of at least 1%. Investigation 
of the functional genomic distribution of the least sta-
ble CpGs over time (|Δβ| ≥ 0.10) revealed the major-
ity of CpGs fell within Open Seas, while 12 fell within 
CpG Islands, and the remaining in CpG Shores and 
Shelves (Fig.  2). In summary, 34,776 CpG sites showed 
a nominally significant difference over time (unadjusted 
p-value < 0.05), after correcting for age, sex, smoking and 
cell composition estimates. However, not a single locus 
withstood correction for multiple testing (FDR-corrected 
p-value < 0.05).
Fig. 1 Boxplot depicting the log10 mean change in methylation (β) 
between baseline and 1‑year follow‑up visit
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Methylation association analysis
We performed an exploratory analysis looking for associ-
ations between LEQ scores and DNAm in individual CpG 
probes in the vicinity of candidate genes previously impli-
cated in the stress response and in the most variable CpG 
sites across the epigenome. Methylation at a single CpG 
site (cg15212455; POU6F2; “POU class 6 homeobox  2”; 
chr 7) was associated with impact ratings of total LEQ 
scores with a suggestive significance of p < 1.0 × 10−5, 
although not a single locus withstood correction for mul-
tiple testing (FDR-corrected p > 0.05 for all comparisons). 
Figure 3 shows the Manhattan plot depicting all analyzed 
CpG sites with their calculated p-values for the associa-
tion between DNAm and total LEQ scores. Table 2 lists 
the top 20 loci associated at nominal significance with 
total LEQ scores. Inspection of quantile–quantile (QQ) 
plots did not show evidence for inflation or bias (Fig. 4; 
Lambda factor = 0.98). Manhattan plots and associated 
QQ plots for additional association analyses can be found 
in Additional file  1: Fig. S3–S8. The sensitivity analy-
sis, excluding subjects who did not take psychotropic 
drugs at the time of testing, did not yield signification 
associations. These results, specific to modeling the asso-
ciation between DNAm and total LEQ scores, are pre-
sented in Additional file 1: Figs. S9 and S10.
Epigenetic aging
As expected, there was a strong positive correlation 
between individuals’ DNAm age and chronological 
age (r = 0.941, p < 0.001; see Additional file  1: Fig. S11). 
According to Horvath’s estimate, the mean (SD, range) 
AA was − 0.23 years (3.71, range − 9.94 to 9.86 years) at 
baseline and 0.25 years (3.95, range − 8.12 to 9.43 years) 
at the 1-year follow-up. Between visits, the mean (SD, 
range) change in AA was 0.50 years (4.97, range − 10.72 
to 13.85  years). Overall, no statistically significant asso-
ciations between epigenetic aging and symptom or stress 
measures were detected.
Additional analyses
We included genes mapped by the top CpG sites (unad-
justed p < 0.05) associated with total LEQ scores in an 
enrichment analysis. No biological processes survived 
FDR correction (see Additional file  1: Table  S3). Blood 
brain correlation coefficients for methylation of the top 
20 loci associated with total LEQ scores (overlapping 
with the 450 K Beadchip array) are presented in Table 3. 
Eight of the top 20 most differentially methylated loci 
associated with total LEQ scores showed a significant 
correlation between methylation in the blood and meth-
ylation in at least one brain region. Methylation of the 
CpG site that was most strongly associated with total 
LEQ scores was significantly correlated with methylation 
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Fig. 2 Functional genomic distribution for the least stable CpG sites 
over 1‑year period (|Δβ| ≥ 0.10). a Depicts the distribution of probes 
that fell within CpG Islands (12/66), Shelves (7/66), Shores (11/66) and 
the Open Sea (36/66). b Depicts the distribution of probes that fell 
within the gene body (28), 5’ UTR (11), 3’ UTR (2), 1st Exon (4), TSS 1500 
(19) and TSS 200 (6)
Fig. 3 Manhattan plot for association between DNA methylation 
and total LEQ scores. The horizontal red line represents the 
epigenome‑wide significant threshold for this study (p < 6.6 × 10−7) 
and the blue line represents a suggestive significance threshold 
(p < 1.0 × 10−5)
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Discussion
To the best of our knowledge, our study is the first to 
investigate epigenome-wide methylation changes over 
time in BD patients. Moreover, it is the first to explore 
methylation changes related to non-traumatic stress-
ful life events on an epigenome-wide scale. Although 
no locus withstood correction for multiple testing, our 
suggestive findings and secondary analyses provide lim-
ited evidence supporting a role of DNAm in association 
with non-traumatic life events in chronic BD patients.
We identified a single, suggestively significant, CpG 
site associated with total LEQ scores, mapping to 
POU6F2, which has been associated with several psy-
chiatric traits as well as intelligence and educational 
attainment. More specifically, genome-wide association 
studies have identified POU6F2 risk variants associated 
with psychological distress (Koshimizu et  al. 2019), 
feeling emotionally hurt (Nagel et  al. 2018), schizo-
phrenia (Goes et al. 2015), autism (Anney et al. 2010), 
educational attainment (Lee et  al. 2018; Okbay et  al. 
2016) and intelligence (Hill et  al. 2018; Davies et  al. 
2018). Additionally, in a longitudinal investigation of 
DNAm changes preceding adolescent psychotic expe-
riences, DNAm of the CpG site cg11604728 (POU6F2) 
measured at age 15–17 was among the top 20 CpG sites 
indicative of psychotic experiences at age 18 (Roberts 
et al. 2019). Furthermore, POU6F2 is highly expressed 
in the brain with the highest expression found in the 
frontal cortex (Additional file 1: Fig. S13) and methyla-
tion of our suggestive CpG site in blood is correlated 
with methylation in brain tissue across multiple brain 
regions. Interestingly, another of our top 20 CpG sites 
(cg26822318) falls in proximity to the FER1L6 gene, of 
which a variant (rs4870888) has been associated with 
suicide attempts in a meta-analysis of major depres-
sive disorder, schizophrenia and BD (Mullins et  al. 
2019). Furthermore, another GWAS reported a FER1L6 
Table 2 Top 20 CpG sites associated with total LEQ scores
Probe t value p-value FDR-corrected 
p-value
Chr Relation to island Annotated gene
cg15212455 − 4.87 3.56E−06 0.263 chr7 Open Sea POU6F2
cg05335886 − 4.55 1.02E−05 0.263 chr16 Island TMC5
cg09725915 4.54 1.05E−05 0.263 chr2 Island
cg24511004 4.43 1.62E−05 0.263 chr1 Open Sea
cg18110277 − 4.50 1.74E−05 0.263 chr2 Open Sea
cg21516302 − 4.24 4.58E−05 0.575 chr2 Open Sea
cg05180443 − 4.04 8.61E−05 0.927 chr17 Island CHAD; ACSF2
cg01440452 − 3.97 1.03E−04 0.946 chr5 N Shore PURA 
cg26730347 − 4.00 1.20E−04 0.946 chr22 N Shore SLC5A1
cg15869582 3.94 1.26E−04 0.946 chr6 S Shore IBTK
cg05919744 3.95 1.44E−04 0.977 chr11 S Shore SLC22A18AS;SLC22A18
cg26822318 3.86 1.61E−04 0.977 chr8 Open Sea FER1L6
cg27296293 − 3.80 1.98E−04 0.977 chr11 Island RP11‑748H22.1; TRPC6
cg06334363 3.82 2.01E−04 0.977 chr9 S Shore RP11‑235C23.5; FKTN
cg00356897 − 3.79 2.30E−04 0.977 chr1 Open Sea RP4‑594I10.2
cg24795825 3.72 2.98E−04 0.977 chr15 N Shore MORF4L1
cg17984201 3.69 3.17E−04 0.977 chr13 Open Sea
cg18002447 − 3.67 3.20E−04 0.977 chr17 Island
cg07349208 − 3.66 3.36E−04 0.977 chr4 Island RP11‑380D23.2
cg05705044 3.65 3.38E−04 0.977 chr11 S Shore RBM7
Fig. 4 QQ plot. The plot shows no evidence for inflation or bias in 
the association analysis of DNA methylation with total LEQ scores 
(Lambda = 1.04)
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variant (rs10481151) suggestively associated with cog-
nitive performance (Need et al. 2009).
At the current sample size, our study provides only 
minimal evidence supporting an association between 
methylation of individual CpGs and non-traumatic, 
recent stressful life events in BD. These findings, however, 
corroborate other reports of a limited role of DNAm with 
non-traumatic stress (Marzi et  al. 2018). Noteworthy, a 
recent study reported hypermethylation of KITLG asso-
ciated with childhood trauma in healthy controls (n = 91) 
but not in bipolar patients (n = 50) (He et  al. 2018). 
Although the mechanistic role of DNAm in the pheno-
typic expression of early life adversities is well established 
in the literature, other mechanisms may be responsible 
in adulthood and in association with subsequent events. 
This notion aligns with theories such as Post’s kindling 
hypothesis and the decay model which suggest a higher 
impact of life events on first episode than on subsequent 
episodes in BD (Aldinger and Schulze 2017; Kemner et al. 
2015; Hillegers et al. 2004). Furthermore, it must be con-
sidered whether positive epigenetic associations with life 
events could be disorder-specific, genotype-dependent, 
associated with specific trauma exposure, age groups, 
sex and/or tissues measured (Marzi et  al. 2018; Vinkers 
et al. 2015; Uddin et al. 2010; Boks et al. 2015; Smith et al. 
2011; Mehta et  al. 2017). While there is no gold stand-
ard for life stress measurements, differences in how to 
quantify stress may also have a major effect on findings 
(Johnson 2005; Bender and Alloy 2011; Monroe 2008; 
Dohrenwend 2010; Brown and Harris 2012).
The main strength of our study is its longitudinal 
design, allowing for repeated measures within individu-
als and to investigate methylation changes over time and 
in relation to symptomatology and stressful life events. 
To the best of our knowledge, this is the first study to 
collect repeated epigenome-wide methylation measures 
in bipolar patients. Furthermore, our study paid attention 
to critical confounding factors which often lead to spuri-
ous findings. For example, the use of methylation-based 
smoking scores better controls for the extent of smok-
ing throughout the lifetime than the use of self-reported 
smoking measures (Elliott et  al. 2014; Shenker et  al. 
2013). Finally, in contrast to most other studies, we have 
included an exploratory epigenome-wide approach.
Despite the strengths of our study, several limitations 
need to be addressed. First, our study was limited by 
our small sample size which makes identifying subtle 
differences in methylation difficult. Taking power into 
consideration, and as an attempt to address the inher-
ent multiple testing problem associated with EWAS, we 
limited our EWAS to only the most variable CpG sites 
according to MAD scores. While the fact that not a 
single site-specific association in DNAm survived cor-
rection for multiple testing could reflect the limited sta-
tistical power of our small sample, it may also be related 
to an overly conservative multiple testing correction 
considering the lack of variability in methylation at 
many CpGs and spatial correlation of methylation with 
nearby sites (Walker et al. 2016; Lunnon et al. 2015). A 
recent study estimated there are approximately 530,000 
independent tests in a whole blood EPIC array DNAm 
study. Accordingly, they proposed a corrected signifi-
cance threshold of 9.42 × 10−8 to be used as a standard 
threshold for future EWAS based on the EPIC array 
(Mansell et  al. 2019). Furthermore, the study intro-
duced a freely available online tool which allows users 
to perform power calculations to guide sample sizes, 
accounting for the individual properties of each DNAm 
site and using their empirically derived significance 
threshold. According to their tool, an effect size of just 
Table 3 Blood-brain methylation correlation for top differentially methylated CpGs associated with total LEQ scores
PFC prefrontal cortex, EC entorhinal cortex, STG superior temporal gyrus, CER cerebellum
Significant correlations in italics
Probe Blood-PFC p-value Blood-EC p-value Blood-STG p-value Blood-CER p-value
cg15212455 0.721 4.16E−13 0.731 4.64E−13 0.747 1.48E−14 0.631 3.71E−09
cg05335886 − 0.086 0.467 − 0.101 0.404 − 0.145 0.213 − 0.155 0.196
cg09725915 0.576 7.86E−08 0.532 1.76E−06 0.626 1.96E−09 0.489 1.49E−05
cg21516302 0.373 0.001 0.522 3.01E−06 0.507 3.46E−06 0.307 0.009
cg05180443 0.204 0.081 0.336 0.004 0.298 0.009 0.175 0.144
cg01440452 − 0.097 0.413 0.062 0.606 − 0.119 0.309 0.020 0.870
cg26730347 0.499 6.05E−06 0.568 2.33E−07 0.562 1.51E−07 0.493 1.27E−05
cg27296293 0.131 0.265 − 0.214 0.073 0.037 0.755 0.236 0.048
cg24795825 0.016 0.894 0.299 0.011 0.247 0.033 0.121 0.317
cg18002447 0.038 0.749 0.034 0.776 0.042 0.720 − 0.262 0.028
cg07349208 0.167 0.156 0.095 0.431 − 0.112 0.338 0.068 0.571
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1% difference between cases and controls would require 
a sample of 1000 participants, for only a third of meth-
ylation sites to have > 80% power. We observed an effect 
size below 5% in our study (based on median split) for 
our most significantly associated site, indicating that 
our study is nevertheless underpowered. Future stud-
ies should take advantage of this tool to assess, a priori, 
required sample sizes according to their expected effect 
sizes. Furthermore, complementary systems biology 
approaches such as weighted gene co-methylation net-
work analysis (WGCNA) could be beneficial for studies 
with limited sample sizes, providing more insight into 
the functional role of altered DNAm (Langfelder and 
Horvath 2008).
Another limitation is in relation to the fact that our 
sample represents a cohort of chronic BD patients 
which likely influenced our investigation of epigenetic 
aging related to symptom ratings over time. The chro-
nicity of patients may also confound our findings with 
regards to the heterogenous treatments patients have 
received over the years. To acknowledge this critical 
factor, we conducted a sensitivity analysis excluding 
those subjects not taking psychotropic drugs at the 
time of testing, however, this also did not lead to sig-
nificant results. One must also consider the possible 
recall and desirability biases associated with self-rating 
questionnaires like the LEQ and CTS. Lastly, little is 
known about the temporal stability of epigenetic mark-
ers (Byun et al. 2012; Talens et al. 2010). We cannot be 
sure whether the time interval of 1  year was too long 
or short to observe dramatic methylation changes or at 
what time window following exposure to stressful life 
events one might observe changed methylation profiles.
Conclusions
BD is a multifactorial psychiatric illness, and for many 
patients full interepisodic remission never occurs (Sam 
et  al. 2019). Stressful life events have been associ-
ated with a worse course of BD (Aldinger and Schulze 
2017) and there remains a need to better understand 
the mechanisms which allow these stressors to bring 
about phenotypic change. Our study provides limited 
evidence supporting an association between DNAm 
and recent, non-traumatic stressful life events in BD 
patients. As findings in clinical populations have been 
inconsistent, there is still much to be understood espe-
cially with regards to the temporal nature of environ-
mentally induced DNA modifications. Future larger 
studies of well-characterized patients, longitudinal in 
design, are warranted.
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